Can Lorlatinib/Lorlatinib (Borina) be stopped once taken?

Lorlatinib/Lorlatinib (Lorlatinib) is used for patients with ALK-positive non-small cell lung cancer, especially those who are resistant to the first or second generationALK inhibitors and have brain metastases. The course of treatment usually requires long-term maintenance. Clinical guidelines emphasize that stopping treatment may lead to tumor recurrence or acceleration of drug resistance, especially for patients with brain metastases. Once treatment is stopped, tumors may progress rapidly, posing serious risks. Therefore, patients cannot stop taking the medicine at will, and all adjustments must be made under the guidance of a doctor.

In clinical application, regular imaging examinations should be performed during the treatment of lorlatinib to monitor changes in tumor size and brain metastasis. At the same time, laboratory examinations of blood lipids, liver function, and nervous system should be performed to detect side effects in a timely manner. Common side effects include elevated blood lipids, mild neurological symptoms, and mild abnormalities in liver function, which can usually be managed with dose adjustments or adjunctive medications. For well-tolerated patients, physicians can balance efficacy and safety by optimizing doses based on clinical response rather than discontinuing the drug completely.

The discontinuation strategy must be individualized and should be combined with a comprehensive assessment of tumor burden, disease progression, and patient tolerance. Long-term maintenance therapy can inhibit tumor growth to the greatest extent, extend progression-free survival, and improve quality of life. Before any adjustment of the course of treatment or discontinuation of medication, doctors need to assess the risks to ensure that while the patient obtains curative effect, side effects are controllable and relapse or serious complications are avoided. As a third-generation ALK inhibitor, the long-term medication concept of lorlatinib emphasizes continuous control and scientific management, making the treatment safer and more effective. At the same time, patients should maintain a regular life, a balanced diet and moderate exercise during the medication period to assist the medication in exerting its best effect and enhance the overall quality of life.

Reference materials：https://www.lorbrena.com/